Оптимальный целевой уровень гемоглобина при лечении эритропоэз-стимулирующими агентами анемии при хронической болезни почек: спорные вопросы


Л.В. Козловская, Ю.С. Милованов, Л.Ю. Милованова

ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, Москва
Обсуждаются противоречия в интерпретации целевого уровня гемоглобина при хронической болезни почек и подходы к оптимизации стратегии применения препаратов, стимулирующих эритропоэз.

Литература


1. Mc Clellan W., Aronoff S.L., Bolton W.K. et al. The prevalence of anemia in patients with chronic kidney disease. Curr. Med. Ress. Opion. 2004; 20: 1501–1510.
2. Orbador G.T., Roberts T., St Peter W.L. et al. Trends in anemia at initiator of dialysis in the United States. Kidney Int. 2001; 60: 1875–1884.
3. Bansal N., Tighiouart H., Weiner D. et al. M. Anemia as a Risk Factor for Kidney Function Decline in Individuals With Heart Failure. Am. J. Cardiol. 2007; 99: 1137–1142.
4. Tong P.C., Kong A.P., So W.Y. et al. Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in clinese patients with type 2 diabetes. Diabetes Care. 2006; 29: 2439–2444.
5. Kovesdy C.P., Trivedy B.K., Kalantar-Zaden K. et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006; 69: 560–564.
6. Li S., Foley R.N., Collins A. J. Anemia and cardiovascular disease, Hospitalization, and stage renal disease, and death in older patients with chronic kidney disease. Int. Urol. Nephrol. 2005; 37(2): 395–402.
7. Thorp M.L., Jonson E.S. Effect of anemia on mortality? Cardiovascular hospitalization? And stage renal disease among patients with chronic renal disease. Nephrology. 2009; 14: 240–246.
8. Locatelli F., Conte F., Marcelli D. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity – the experience of the Lombardy dialysis registry. Nephrol. Dial. Transplant. 1998; 13: 1642–1644.
9. Mocks J., Franke W., Ehmer B. et al. Analysis of safety database for long term epoetin beta treatment. A meta analysis covering 3697 patients. In: Koch K.M, Stein G. eds. Pathogenetic and Therapeutic Aspects of Chronic renal failure. Marcel Dekker, New York, 1997; 163–179.
10. Ma J.Z., Ebben J., Xia H., Collins A.J. Hematocrit level and associated mortality in hemodialysis patients. J. Am. Soc. Neprol. 1999; 10: 610–619.
11. Collins A.J. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int. 2002; 61[Suppl. 80]: S44–S48.
12. Locatelli F., Pisoni R.L., Combe C. et al. Anaemia in five European countries and associated morbidity and mortality among haemodialysis patients: results from the dialysis outcomes and practice patterns study (DOPPS). Nephrol. Dial. Transplant. 2004; 19: 121–132.
13. Thorp M.L., Johnson E.S. Effect of anemia on mortality, Cardiovascular Hospitalizations and End Stage Renal Disease among patients with chronic renal desease. Nephrology. 2009; 14: 240–246.
14. Drueke T.B., Locatelli F., Cyne N. et al. CREATE Investidators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New. Engl. J. Med. 2006; 355(20): 2071–2084.
15. Singh A.K., Szczech L., Tang K.L. et al. CHOIR Investidators. Correction of anemia with epoetin alfa of chronic kidney disease. New. Engl. J. Med. 2006; 355(20): 2085–2098.
16. Besarab A, Bolton W.K., Browne J.K. The effects of normal as compared with low are receiving hemodialysis and epoetin. N. Engl. J. Med. 1998; 339: 584–590.
17. Foley R.N., Perfrey P.S., Morgan J. et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000; 58: 1325–1335.
18. Strippoli G.F., Manno C., Schena F.P., Craig J.C. Haemoglobin abd haematocrit targets for the anaemia of chronic renal disease (Cochrane rewiev). Cochrane database Syst. Rew. 2003; 1: CD003967.
19. Furland H., Linde T., Ahlmen J. et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol. Dial. Transplant. 2003; 28: 353–361.
20. Rossert J., Levin A., Roger C.R. et al. Effect of larsy correction of anemia on the progression of chronic kidney disease. Am. J. Kidney Dis. 2006; 47: 738–750.
21. Locatelli F., Covic A., Eckardt K.U. et al. Anaemia management in patients with chrjnic kidney disease: a position statement by the Anaemia Working Group of European renal Best Practice (ERBP). Nephrol. Dial. Transplant. 2009; 24: 348–354.
22. Levin A. The treatment of anemia in chronic kidney disease: under standing in 2006, Curr. Opin. Nephrol. Hypertens. 2007; 16: 267–273.
23. De Francisco A.L. Individualizing anemia therapy. Nephrol. Dial. Transplant. 2010; 3(6): 519–526.
24. Phrommintikul A., Haas S.J., Elsik M. et al. Mortality and target haemoglobin concentrations in anemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007; 369:381–388.
25. Locatelli F., Aljama P., Canaud B. et al. Targer haemoglobin to aim for with erytropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Study. Nephrol. Dial. Transplant. 2010; 25: 2846–2850.
26. Szczech L.A., Barnhart H.X., Inrig J.K. et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008; 74: 791–798.
27. Szczech L.A., Barnhart H.X., Sapp S. et. al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 2010; 77: 239–246.
28. Kilpatrick R.D., Critchlow C.W., Fishbane S. et. al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008; 3: 1077–1083.
29. Ebben J.P., Gilbertson D.T., Foley R.N. et al. Hemoglobin level variability: assotiation with comorbidity, intercurrent events, and hospitalizations. Clin. J. Am. Soc. Nephrol. 2006: 1: 1205–1210.
30. Gilbertson D., Ebben J., Foley R.N. Hemoglobin level variability: assotiation with mortality. Clin. J. Am. Soc. Nephrol. 2008; 3: 133–138.
31. Feldman H.I., Israni R.K., Yang W. et al. Hemoglobin variability and mortality among hemodialysis patients. J. Am. Soc. Nephrol. 2006: 17: 583A (abstract SA-PO034).
32. Besarab A., Goodkin D.A., Nissenson A.R. The Normal Hematocrit. Study Followup. N. Engl. J. Med., 2008; 358: 433–434.
33. Strippoli G.F., Navaneethan S.D., Craig J.C. Hemoglobin and hematocrit targets for the anemia of chronic kidney disease. Cochrane Database Syst. Rev. 2006; 18(40): CD003967.
34. Козловская Л.В., Милованов Ю.С., Милованова Л.Ю. и др. Трудности лечения почечной анемии. Место активаторов рецепторов эритропоэтина длительного действия. Клин. нефрол., 2010; 2: 23–27.
35. Ofsthun N.J. The association of mortality and hospitalization with haemoglobin and missrd dialysis treatments in stage 5 CKD patients with and without cardiac comorbidities. Nephrol. Dial. Transplant. 2005; 20(Suppl. 5): MP 2004 (Abstr.)
36. Ishani A., Guo H., Gilbertson D.T. et al. Time to target haemoglobin concentration (11g/dL): risk of hospitalization and mortality among incident dialysis patients. Nephrol. Dial. Transplant. 2007; 22: 2247–2255.
37. Macdougall I.C., Walker R., Provenzano R. et al. ARCTOS Study Investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin. J. Am. Soc. Nephrol. 2008; 3 (2):337–347.
38. Besarab A., Bolton W.K., Browne J.K. The effects of normal as compared with low are receiving hemodialysis and epoetin. N. Engl. J. Med. 1998; 339: 584–590. 39. Nissenson A.R., Swan S.K., Lindberg J.S. et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am. J. Kidney Dis. 2002; 40: 110–118.
40. Aranesp Summary of product Characteristics. Angen Europe B.V. Breda. The Netheriands.
41. Toto R.D., Pichette V., Navarro J. et al. darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every other-week administration. Am. J. Nephrol. 2004; 24: 453–460.
42. Agarwal A., Silver M.R., Reed J.E. et al. An open-lebel study of darbepoetin alfa administered once monthly for the maintenance of hemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J. Int. Med. 2006; 260: 577–585.
43. Toto R.D., Pichette V., Navarro J. et al. darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every other-week administration. Am. J. Nephrol. 2004; 24: 453–460.
44. Kaufman J.S., Reda D.J., Fue C.L. et al. Subcutaneus compared with intravenous epoetin in patients receiving hemodialysis. N. Engl. Med. 1998; 339: 578–583.
45. Carrera F., Oliveira L., Maia P. et. al. The intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on hemodialysis. Nephrol. Dial. Transplant. 2006; 21: 2846–2850.


46. Molina M., Garcia Hemandez M.A., Narraro M.J. et al. Estudio comparative sobre et tratamiento de la anemia renal en el pacienteen hemo dialysis cambio de via de administraci en de epoetina alfa frente a conversion a darbepoetina. Nefrologia. 2004; 14: 564–571.
47. Pfeffer M.A., Burdmann E.A., Chen C.Y. et al. Treat Investigators. A trial of darbepoetin alfa in tipe 2 diabetes and chronic kidney disease. N. Engl. J. Med. 2009; 361(21): 2019–2032.
48. Wiesholzer M. Switch from rHuEPO to darbepoetin alfa in hemodialysis patients in a clinical setting. Nephrol. Dial. Transplant. 2006; 21(Suppl. 4): iv154–iv155
49. Tanghe A., Rooryck N., von Knorring J. et al. Economic benefits of less frequent dosing of erythropoiesis stimulating proteins in patients on dialysis. Poster presented at the 35th European Symposium on Clinical Pharmacy. October 2006; Vienna. Austria.
50. Eckardt K.U., Kim J., Kronenberg F. et al. Hemoglobin variability does not predict mortality in European hemodialysis patients. J. A. Soc. Nephrol. 2010 [Epub ahead of print].
51. Locatelli F., Nissenson A.R., Barrett B.J. et al. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease Improving Global Outcomes (KDIGO). Kidney Int. 2008; 74:1237–1240.
52. Bohlius J., Schmidlin K., Brillant C. et al. Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Lancet 2009;373:1532–1542.
53. Fishbane S., Berns J.S. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005; 68: 1337–1343.
54. Macdougall L.C., Cooper A.C. Nephrol Dial Transplant 2002; 17 (Suppl. 11): 30–49.
55. Gaweda A.E., Nathanson B.H., Jacobs A.A. et al Determining optimum hemoglobin sampling for anemia management from every-treatment data. Clin. J. Am. Soc. Nephrol. 2010; 5(11): 1939–1945.
56. Roche date on file. Date on file. 2007.
57. Tonelli M., Hemmelgarn B. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180(11):E62–E71.
58. Glaspy J., Crawford J., Vansteenkiste J. et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer. 2010; 102(2): 301–315.


Об авторах / Для корреспонденции


Козловская Л.В. – профессор кафедры терапии и профболезней МПФ, ведущий научный сотрудник отдела нефрологии НИИ уронефрологии и репродуктивного здоровья человека ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, д.м.н.;
Милованов Ю.С. – ведущий научный сотрудник отдела нефрологии НИИ уронефрологии и репродуктивного здоровья человека ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, д.м.н.;
Милованова Л.Ю. – научный сотрудник отдела нефрологии НИИ уронефрологии и репродуктивного здоровья человека ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, к.м.н.
E-mail: lussya2000@mail.ru


Похожие статьи


Бионика Медиа